
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Diabetes & Obesity Series
Subscribe to RSS feed of this series
Dr. Richard Gregg
Chief Scientific Officer
Vitae Pharmaceuticals
Dr. Gregg offers insight into the development of obesity drugs, and how co-morbidities factor into development, as well as how it impacts sites and CROs in Phase I through III trials.
Others in the Series
Associations and Societies
Clinical Trials
Articles, Multimedia
Associations and Societies
Clinical Trials






